On 21 March 2024, Thomas Cueni, Director General, IFPMA delivered a statement at the 9th Meeting of the INB in an open session with relevant stakeholders focusing on critical elements for a pandemic agreement. IFPMA strongly supports the efforts to find agreement on a Pandemic Accord and we reaffirm our full commitment to constructively...
Read moreOn 18 March 2024, IFPMA submitted and delivered statements at the 9th Meeting of the Intergovernmental Negotiating Body (INB). The full submitted statement is below.
Read moreIn response to the threat of future global pandemics, the biopharmaceutical industry developed a set of commitments for equitable access to essential medical countermeasures in future pandemics.
Read moreOn 8 March 2024, IFPMA delivered a statement at the resumed session of the 7th Meeting of the Working Group on Amendments to the International Health Regulations in Geneva, where the focus of discussions was on equity.
Read moreIFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read moreAs discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
On 23 February, ahead of the 13th WTO Ministerial Conference, IFPMA and member associations from 10 countries issued a joint statement calling on trade ministers to commit to a comprehensive trade and health agenda that will strengthen the innovation ecosystem, remove trade barriers, promote trade facilitation, strengthen regulatory systems, and address under-resourced healthcare infrastructure.
Read moreOn 23 February 2024, IFPMA submitted a statement at the Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) and the Working Group on the Amendments to the International Health Regulations (2005) (WGIHR) in Geneva, Switzerland.
Read moreOn 19 February in Geneva, Switzerland, IFPMA delivered a statement at the 8th Meeting of the Intergovernmental Negotiating Body (INB).
Read moreThis position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
The fourth meeting of the WHO’s Fair Pricing Forum represents an important opportunity to discuss how the global health community can work together to improve access to medicines and vaccines, deliver on the ambition of the Sustainable Development Goals (SDGs), and to achieve Universal Health Coverage (UHC) by 2030. IFPMA and our members continue to be committed to these goals and welcome the opportunity to share perspectives on how we can work together to achieve them.
Read more